162 related articles for article (PubMed ID: 16023653)
1. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial.
Hu P; Greendale GA; Palla SL; Reboussin BA; Herrington DM; Barrett-Connor E; Reuben DB
Atherosclerosis; 2006 Apr; 185(2):347-52. PubMed ID: 16023653
[TBL] [Abstract][Full Text] [Related]
2. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
[TBL] [Abstract][Full Text] [Related]
3. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women.
Wakatsuki A; Ikenoue N; Shinohara K; Watanabe K; Fukaya T
Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):571-6. PubMed ID: 14699021
[TBL] [Abstract][Full Text] [Related]
4. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
JAMA; 1996 Nov; 276(17):1389-96. PubMed ID: 8892713
[TBL] [Abstract][Full Text] [Related]
5. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women.
Koh KK; Jin DK; Yang SH; Lee SK; Hwang HY; Kang MH; Kim W; Kim DS; Choi IS; Shin EK
Circulation; 2001 Apr; 103(15):1961-6. PubMed ID: 11306524
[TBL] [Abstract][Full Text] [Related]
6. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
[TBL] [Abstract][Full Text] [Related]
7. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation.
Reuben DB; Palla SL; Hu P; Reboussin BA; Crandall C; Herrington DM; Barrett-Connor E; Greendale GA
Am J Med; 2006 Feb; 119(2):167.e1-8. PubMed ID: 16443423
[TBL] [Abstract][Full Text] [Related]
8. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
[TBL] [Abstract][Full Text] [Related]
9. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response.
Silvestri A; Gebara O; Vitale C; Wajngarten M; Leonardo F; Ramires JA; Fini M; Mercuro G; Rosano GM
Circulation; 2003 Jul; 107(25):3165-9. PubMed ID: 12796135
[TBL] [Abstract][Full Text] [Related]
10. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
Ursin G; Palla SL; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Greendale GA
J Clin Oncol; 2004 Jul; 22(14):2842-8. PubMed ID: 15254051
[TBL] [Abstract][Full Text] [Related]
11. Cross-sectional association between markers of inflammation and serum sex steroid levels in the postmenopausal estrogen/progestin interventions trial.
Crandall C; Palla S; Reboussin B; Hu P; Barrett-Connor E; Reuben D; Greendale G
J Womens Health (Larchmt); 2006; 15(1):14-23. PubMed ID: 16417414
[TBL] [Abstract][Full Text] [Related]
12. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators.
Espeland MA; Stefanick ML; Kritz-Silverstein D; Fineberg SE; Waclawiw MA; James MK; Greendale GA
J Clin Endocrinol Metab; 1997 May; 82(5):1549-56. PubMed ID: 9141548
[TBL] [Abstract][Full Text] [Related]
13. Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with Type 2 diabetes.
Manning PJ; Sutherland WH; Allum AR; de Jong SA; Jones SD
Diabet Med; 2002 Oct; 19(10):847-52. PubMed ID: 12358873
[TBL] [Abstract][Full Text] [Related]
14. Effects of continuous combined hormone replacement therapy on inflammation in hypertensive and/or overweight postmenopausal women.
Koh KK; Ahn JY; Jin DK; Yoon BK; Kim HS; Kim DS; Shin MS; Son JW; Choi IS; Shin EK
Arterioscler Thromb Vasc Biol; 2002 Sep; 22(9):1459-64. PubMed ID: 12231566
[TBL] [Abstract][Full Text] [Related]
15. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women.
Sumino H; Ichikawa S; Kasama S; Takahashi T; Kumakura H; Takayama Y; Kanda T; Kurabayashi M
Atherosclerosis; 2006 Dec; 189(2):436-42. PubMed ID: 16469323
[TBL] [Abstract][Full Text] [Related]
16. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women.
Barrett-Connor E; Slone S; Greendale G; Kritz-Silverstein D; Espeland M; Johnson SR; Waclawiw M; Fineberg SE
Maturitas; 1997 Jul; 27(3):261-74. PubMed ID: 9288699
[TBL] [Abstract][Full Text] [Related]
17. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen.
Wakatsuki A; Okatani Y; Ikenoue N; Fukaya T
Circulation; 2002 Mar; 105(12):1436-9. PubMed ID: 11914251
[TBL] [Abstract][Full Text] [Related]
18. Effects of estrogen with and without progestin on urinary incontinence.
Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG
JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164
[TBL] [Abstract][Full Text] [Related]
19. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
[TBL] [Abstract][Full Text] [Related]
20. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease.
Yeboah J; Klein K; Brosnihan B; Reboussin D; Herrington DM
Menopause; 2008; 15(6):1060-4. PubMed ID: 18521047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
